25-hydroxycholecalciferol

25‑hydroxycholecalciferol, also known as calcifediol or 25‑hydroxyvitamin D3 (25(OH)D), is the primary circulating form of vitamin D in the bloodstream and serves as the best clinical indicator of an individual's vitamin D status. It is produced endogenously in the liver through the hydroxylation of cholecalciferol (vitamin D3) derived from skin synthesis under UVB exposure, certain foods, or supplements. Both vitamin D2 and D3 are converted first in the liver to their 25‑hydroxy forms before undergoing further hydroxylation in the kidney to form the hormonally active 1,25‑dihydroxyvitamin D (calcitriol). This latter molecule binds to the vitamin D receptor in target tissues to regulate calcium and phosphorus homeostasis and myriad other physiological processes. 25‑hydroxycholecalciferol has a half‑life of approximately 15 to 30 days, making it stable enough to reflect longer‑term vitamin D exposure. It circulates tightly bound to the vitamin D binding protein (DBP) in blood, and concentrations can be measured in clinical practice to assess sufficiency, insufficiency, or deficiency. In addition to its role in human health, 25‑hydroxycholecalciferol is also used in animal nutrition and research due to its more direct bioavailability compared to cholecalciferol. The compound’s chemical structure (C27H44O2) includes a hydroxyl group at the 25th carbon, which distinguishes it from parent vitamin D3 and facilitates its role as a precursor to the active hormone. While the measurement of serum 25(OH)D is standardized in nmol/L or ng/mL, laboratories may vary in assay methods, necessitating clinical interpretation in context. Importantly, levels below 30 nmol/L (<12 ng/mL) are associated with deficiency, increased risk of osteomalacia and rickets, whereas levels above 50 nmol/L (≥20 ng/mL) are generally considered adequate for health, with some expert groups advocating higher optimal targets for specific populations.

As the major circulating form of vitamin D, 25‑hydroxycholecalciferol plays an indispensable role in human physiology. Fundamentally, it serves as the precursor to the hormonally active form of vitamin D, calcitriol, which is central to calcium and phosphorus metabolism. Calcitriol increases intestinal absorption of calcium, maintaining serum levels essential for bone mineralization and neuromuscular function. Inadequate levels can lead to insufficient calcium absorption, resulting in poorly mineralized bone and disorders such as rickets in children and osteomalacia in adults. The endocrine functions of vitamin D extend beyond bone health; vitamin D receptors are expressed in immune cells, pancreatic β‑cells, and muscle. Immune modulation by vitamin D metabolites is suggested to downregulate pro‑inflammatory cytokines and upregulate antimicrobial peptides, though definitive clinical benefits beyond bone health remain under investigation. Some meta‑analyses indicate that maintaining sufficient serum 25(OH)D may reduce risks associated with respiratory infections, autoimmune conditions, and certain cancers, but findings are heterogeneous and not uniformly accepted. Research comparing calcifediol supplementation to cholecalciferol has shown that 25‑hydroxycholecalciferol can raise serum 25(OH)D levels more rapidly and efficiently, making it a potentially valuable option in individuals requiring rapid repletion, such as those with malabsorption syndromes, obesity, or chronic kidney disease. Evidence also suggests that circulating 25(OH)D correlates with lower parathyroid hormone levels and improved bone density markers in randomized controlled trials. However, while observational studies link low 25(OH)D status with a wide range of chronic conditions including cardiovascular disease and diabetes, causality has not been established across these outcomes, and routine supplementation for these indications is not universally recommended. Mechanistically, vitamin D impacts gene transcription through the vitamin D receptor as a transcription factor, influencing cell proliferation, differentiation, apoptosis, and immune pathways. Collectively, the evidence supports the critical role of 25‑hydroxycholecalciferol in skeletal health, calcium homeostasis, and possibly immune function, but more research is needed to conclusively define its benefits in non‑skeletal systems.

Because 25‑hydroxycholecalciferol represents the circulating form of vitamin D, nutritional recommendations are expressed in terms of its precursors, vitamin D2 and D3. The NIH Office of Dietary Supplements outlines Recommended Dietary Allowances (RDAs) for vitamin D to achieve adequate serum 25(OH)D concentrations to meet the needs of nearly all healthy individuals. For infants 0–12 months, the adequate intake is approximately 10 mcg (400 IU) per day. Children and adults from age 1 to 70 years generally require 15 mcg (600 IU) per day, while adults over age 70 benefit from 20 mcg (800 IU) daily to counteract reduced skin synthesis and renal activation. Pregnant and lactating women mirror adult RDAs at 15 mcg (600 IU) per day. These values are intended to maintain serum 25(OH)D concentrations above 50 nmol/L (20 ng/mL), considered adequate for bone health. Factors influencing needs include limited sun exposure due to geographic latitude, season, sunscreen use, skin pigmentation, age‑related changes in cutaneous synthesis, obesity (sequestration in adipose tissue), and malabsorption syndromes. Individuals with chronic kidney disease or on medications affecting vitamin D metabolism may have altered requirements, and clinicians often monitor serum 25(OH)D to adjust supplementation. It is also important to differentiate between minimum sufficient levels and optimal targets; while the RDA aims to prevent deficiency, some experts recommend higher serum concentrations (30–50 ng/mL) for broader health outcomes, though consensus is not universal. Regular monitoring is important for those at risk of deficiency or with conditions influencing vitamin D metabolism. Ultimately, achieving adequate 25‑hydroxycholecalciferol levels involves a combined strategy of safe sun exposure, diet, and guided supplementation when necessary.

Deficiency of 25‑hydroxycholecalciferol, reflected by low serum 25(OH)D levels, leads first to impaired calcium absorption and consequent hypocalcemia, stimulating parathyroid hormone release and secondary hyperparathyroidism. Clinically, early deficiency may present with nonspecific symptoms including bone pain and muscle weakness. In children, severe deficiency manifests as rickets, characterized by skeletal deformities, growth retardation, widened wrists and ankles, and delayed closure of fontanelles. In adults, prolonged deficiency can cause osteomalacia with diffuse bone pain, increased risk of fractures, and proximal muscle weakness contributing to falls. Laboratory findings often include low serum 25(OH)D, elevated alkaline phosphatase, low normal calcium with compensatory high parathyroid hormone, and in severe cases hypophosphatemia. Populations at high risk for deficiency include individuals with limited sun exposure (northern latitudes, institutionalized elderly), those with dark skin pigmentation (reduced cutaneous synthesis), conditions causing fat malabsorption, obesity, and chronic kidney or liver disease impairing activation. Prevalence data from NHANES indicate that a significant proportion of the U.S. population has serum 25(OH)D levels considered inadequate, with particular disparities observed across age, racial, and ethnic groups. Deficiency can also exacerbate muscular dysfunction, leading to myopathy, increased fall risk, and impaired immune responses. Early detection depends on measuring serum 25(OH)D, as clinical signs often appear late. Addressing deficiency through tailored supplementation and lifestyle modification is crucial to restore optimal levels and mitigate long‑term skeletal and metabolic consequences.

Common Forms: calcifediol, cholecalciferol

Typical Doses: 20–50 μg/day

When to Take: with meals

Best Form: calcifediol

⚠️ Interactions: statins, steroids